May 29, 2020May 29, 2020

Updated Guidelines Recommend Rubraca for Some Prostate Cancer Patients

News

Only a couple of weeks after Rubraca (rucaparib) was approved for the treatment of prostate cancer, the National Comprehensive Cancer Network (NCCN) has updated its guidelines recommending this PARP inhibitor as ... Read more

May 22, 2020May 22, 2020

Rubraca Receives Conditional FDA Approval for metastatic CRPC Patients with BRCA Mutations

News

The U.S. Food and Drug Administration (FDA) has granted conditional approval to Rubraca (rucaparib) for treating patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA mutations who have previously received ... Read more